Re-evaluating perioperative and neoadjuvant immunotherapy in early-stage lung cancer: Current evidence and discussions Erken evre akciğer kanserinde perioperatif ve neoadjuvan immünoterapinin yeniden değerlendirilmesi: Mevcut kanıtlar ve tartışmalar

Creative Commons License

Erul E.

Tuberkuloz ve Toraks, cilt.73, sa.1, ss.80-84, 2025 (ESCI, Scopus, TRDizin) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 73 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.5578/tt.2025011040
  • Dergi Adı: Tuberkuloz ve Toraks
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.80-84
  • Anahtar Kelimeler: Early-stage lung cancer, immune checkpoint inhibitors, neoadjuvant immunotherapy, non-small cell lung cancer, perioper-ative treatment
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

Early-stage lung cancer remains a challenging disease with a significant risk of recurrence despite treatment. In recent years, there has been growing interest in the application of neoadjuvant and perioperative immunotherapies. The success of immune checkpoint inhibitors in advanced stages has prompted their investigation in earlier disease stages. This editorial examines clinical trials comparing the efficacy of perioperative and neoadjuvant immunotherapies, focusing on their impact on survival, pathological response rates, and toxicity profiles. Furthermore, ongoing debates and the importance of patient-centered decision-making are discussed.